Newsletter | October 28, 2024

10.28.24 -- Bacterial Endotoxin Testing, Part 3: Calculating Endotoxin Limits And MVD

SPONSOR

Nanotechnology To Improve The Performance Of Your Small And Large Molecule Medicines

Christian Jones shares the latest in nanotechnology advancements including recent clinical data, formulation applications, and API optimization to NanoImprove formulations through superior bioavailability, drug loading, route of administration, pill burden, and more.

FEATURED EDITORIAL

Bacterial Endotoxin Testing, Part 3: Calculating Endotoxin Limits And MVD

By Yadnyesh Patel, microbiology subject matter expert

The author continues his article series on bacterial endotoxin testing by discussing depyrogenation and calculating endotoxin limits and maximum valid dilution (MVD), including those for active substances and excipients, combination products, and medical devices.

INDUSTRY INSIGHTS

The Importance Of Understanding Materials In Medical Product Development

White Paper | By Fran DeGrazio, Kymanox Corporation

Explore considerations for the series of characterizations necessary to ensure the efficacy of a packaging or device component and final drug delivery system.

How Drug Delivery Is Enabling A Clinical Trial For Glioblastoma

Webinar | Nanoform

Discover highly promising in-vivo data, enabled by a nanoformed drug product for the treatment of glioblastoma multiforme (GBM).

Sustainability Considerations For Drug Delivery Device End-To-End Solutions

Article | By Barbara Lead, SMC Ltd.

Learn how to address the gradual unlinking of economic activity from the consumption of finite resources and the removal of waste to support and help prevent a global climate catastrophe.

Customized Release Through Dispersed Dosage Formats

Article | By Nathan Dormer, Ph.D., Adare Pharma Solutions

Typically, dosage format is based on the target product profile: how the developer envisions the product best addressing a clinical indication by maintaining population-wide efficacy.

Optimizing Formulations For Subcutaneous And LNP-Based Delivery Methods

Webinar | Catalent

Increased demand for protein delivery and the emergence of advanced modalities – including mRNA – are introducing new challenges to the development lifecycle, such as high-concentration formulations.

SOLUTIONS

Real World Dosing Solutions For Patients

Catalent

Non-Viral Gene Delivery (NVGD) Using Polymeric-Nano Particles

Battelle

Drug Product Fill Finish And Formulation Solutions

Ajinomoto Bio-Pharma Services